study reveals that SGLT2 inhibitors consistently lower the risk of major adverse cardiovascular events by 9% across various patient groups, especially impacting cardiovascular death reduction, highlighting their broad therapeutic potential beyond diabetes management.
3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great
December 27, 2023